Premium CRO Visikol serves all top twenty pharmaceutical companies with advanced tissue imaging and cell culture services, indicating a strong reputation and potential for expanded engagements with current clients or similar large pharma opportunities.

GLP Imaging Recent launch of GLP multiplex imaging services signals a scalable, compliant offering for regulated projects, presenting a clear cross-sell path to clients requiring validated imaging workflows.

BBB Capabilities Development of blood-brain barrier (BBB) assays and BBB models opens a targeted entry point for CNS drug discovery programs, offering opportunities to address permeability and transport challenges with pharma partners.

3D Culture Portfolio Expansion of 3D tissue and precision-cut tissue slice models, including kidney and liver, enhances Visikol’s value proposition for organ-specific efficacy and toxicity studies relevant to early-stage and IND-enabling programs.

Partnership Momentum Strategic collaborations (notably with Standard BioTools) have bolstered imaging capabilities; leveraging existing partnerships can accelerate joint offerings to clients seeking integrated imaging and analytics solutions.